Kamada (KMDA)

Executive Summary

Kamada Ltd. is a vertically integrated Israeli biopharmaceutical company focused on plasma-derived and recombinant protein therapeutics for rare and serious diseases. With a market capitalization of approximately $480 million, the company has established a commercial portfolio of six specialty products, including GLASSIA (Alpha-1 Antitrypsin for AAT deficiency), KamRAB (rabies immunoglobulin), and Cytogam (CMV immune globulin). Kamada also operates a robust development pipeline, highlighted by a Phase 3 trial of Alpha-1 Antitrypsin for AAT deficiency (NCT04204252) with expected completion in 2031, and ongoing studies for Cytogam in CMV prevention post-transplant. The company's strong manufacturing capabilities and existing revenue streams from approved products provide a solid foundation for growth. Key near-term drivers include potential label expansions for Cytogam, progress in the AAT deficiency program, and strategic partnerships to leverage its plasma-derived technology platform. Despite limited near-term pipeline catalysts, Kamada's established commercial presence and focus on niche markets position it for steady growth.

Upcoming Catalysts (preview)

• Q2 2027Cytogam Phase 3 CMV Prevention Trial Interim Data70% success
• Q4 2028Alpha-1 Antitrypsin Phase 3 AAT Deficiency Interim Analysis60% success
• TBDPotential FDA Approval for KamRAB or New Product Launch50% success